CT-P53

BIOLOGICAL2 trials

Sponsors

Celltrion Inc., Celltrion

Conditions

Multiple SclerosisRelapsing-remitting Multiple Sclerosis

Phase 3

A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis

RecruitingNCT05906992

CelltrionRelapsing-remitting Multiple Sclerosis

Start: 2024-01-11End: 2029-01-31Target: 512Updated: 2024-05-22

A Double-blind, Randomized, Active-controlled, Parallel-group, Phase 1/3 study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients with Relapsing-remitting Multiple Sclerosis.

Active, not recruitingCTIS2022-501622-37-00

Celltrion Inc.Multiple Sclerosis

Start: 2024-01-16Target: 432Updated: 2025-07-28